Evidence map›Paper›PMID 36575510›Full record

ArticleJournal of translational medicine2022

Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis.

Esha Baidya Kayal, Sameer Bakhshi, Devasenathipathy Kandasamy, Mehar Chand Sharma, Shah Alam Khan, Venkatesan Sampath Kumar, Kedar Khare, Raju Sharma, Amit Mehndiratta

Abstract read
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esha Baidya KayalCentre for Biomedical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. B.R. Ambedkar Institute-Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences, New Delhi, India.
Devasenathipathy KandasamyDepartment of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.
Mehar Chand SharmaDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Shah Alam KhanDepartment of Orthopaedics, All India Institute of Medical Sciences, New Delhi, India.
Venkatesan Sampath KumarDepartment of Orthopaedics, All India Institute of Medical Sciences, New Delhi, India.
Kedar KhareDepartment of Physics, Indian Institute of Technology Delhi, New Delhi, India.
Raju SharmaDepartment of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.
Amit MehndirattaCentre for Biomedical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India. amit.mehndiratta@keble.oxon.org.ORCID 0000-0001-6477-2462

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly prediction of response to neoadjuvant chemotherapy (NACT) is important to aid personalized treatment in osteosarcoma. Diffusion-weighted Intravoxel Incoherent Motion (IVIM) MRI was used to evaluate the predictive value for response to NACT and survival outcome in osteosarcoma.

methodsTotal fifty-five patients with biopsy-proven osteosarcoma were recruited prospectively, among them 35 patients were further analysed. Patients underwent 3 cycles of NACT (Cisplatin + Doxorubicin) followed by surgery and response adapted adjuvant chemotherapy. Treatment outcomes were histopathological response to NACT (good-response ≥ 50% necrosis and poor-response < 50% necrosis) and survival outcome (event-free survival (EFS) and overall survival (OS)). IVIM MRI was acquired at 1.5T at baseline (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Quantitative IVIM parameters (D, D*, f & D*.f) were estimated using advanced state-of-the-art spatial penalty based IVIM analysis method bi-exponential model with total-variation penalty function (BETV) at 3 time-points and histogram analysis was performed.

resultsGood-responders: Poor-responders ratio was 13 (37%):22 (63%). EFS and OS were 31% and 69% with 16.27 and 25.9 months of median duration respectively. For predicting poor-response to NACT, IVIM parameters showed AUC = 0.87, Sensitivity = 86%, Specificity = 77% at t0, and AUC = 0.96, Sensitivity = 86%, Specificity = 100% at t1. Multivariate Cox regression analysis showed smaller tumour volume (HR = 1.002, p = 0.001) higher ADC-25

conclusionIVIM parameters obtained with a 1.5T scanner along with novel BETV method and their histogram analysis indicating tumour heterogeneity were informative in characterizing NACT response and survival outcome in osteosarcoma.

Indexed as

Bone NeoplasmsOsteosarcomaDiffusion Magnetic Resonance ImagingHumansMagnetic Resonance ImagingNecrosisNeoadjuvant TherapyBiomarkersChemotherapy response evaluationDiffusion weighted imagingIntravoxel incoherent motionOsteosarcomaSurvival outcome

Identifiers

PMID36575510
PMCPMC9795762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.